Pharmacokinetics and safety of extended-release divalproex sodium tablets: Morning versus evening administration

American Journal of Health-System Pharmacy

Volumn 61, Issue 21, 2004, Pages 2280-2283

  Dutta, Sandeep ^a   Reed, Ronald C ^a   Cavanaugh, John H ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Anticonvulsants; Blood levels; Chronopharmacokinetics; Circadian rhythm; Divalproex sodium; Dosage schedules; Pharmacokinetics; Sustained action medications; Toxicity

Indexed keywords

VALPROATE SEMISODIUM; VALPROIC ACID;

ABDOMINAL PAIN; ADULT; ARTICLE; ASTHENIA; BLOOD SAMPLING; CIRCADIAN RHYTHM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG SAFETY; FEMALE; GAS CHROMATOGRAPHY; HEADACHE; HUMAN; MALE; NORMAL HUMAN; OPEN STUDY; PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SOMNOLENCE; SUSTAINED RELEASE PREPARATION;

EID: 12544260259     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/61.21.2280     Document Type: Article

References (25)

1. Brodie MJ, French JA. Management of epilepsy in adolescents and adults. Lancet. 2000; 356:323-9.
2. Browne TR, Holmes GL. Epilepsy. N Engl J Med. 2001; 344:1145-51. [Erratum, N Engl J Med. 2001; 344:1956.]
3. Bowden CL, Brugger AM, Swann AC et al. Efficacy of divalproex vs. lithium and placebo in the treatment of mania. JAMA. 1994; 271:918-24. [Erratum, JAMA. 1994; 271:1830.]
4. Pope HG Jr, McElroy SL, Keck PE Jr et al. Valproate in the treatment of acute mania. A placebo-controlled study. Arch Gen Psychiatry. 1991; 48:62-8.
5. Mathew NT, Saper JR, Silberstein SD et al. Migraine prophylaxis with divalproex. Arch Neurol. 1995; 52:281-6.
6. Wilder BJ, Karas BJ, Hammond EJ et al. Twice-daily dosing of valproate with divalproex. Clin Pharmacol Ther. 1983; 34:501-4.
7. Zarate CA, Tohen M, Narendran R et al. The adverse effect profile and efficacy of divalproex sodium compared with valproic acid: a pharmacoepidemiology study. J Clin Psychiatry. 1999; 60:232-6.
8. Porter RJ. General principles: how to use antiepileptic drugs. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic drugs. 4th ed. New York: Raven; 1995:137-48.
9. Bourgeois BF. Pharmacokinetic properties of current antiepileptic drugs: what improvements are needed? Neurology. 2000; 55(suppl 3):S11-6.
10. Bialer M. Pharmacokinetic evaluation of sustained release formulations of antiepileptic drugs. Clinical implications. Clin Pharmacokinet. 1992; 22:11-21.
11. Depakote ER (divalproex sodium) package insert. North Chicago, IL: Abbott Laboratories; 2003 Jan.
12. Thibault M, Blume WT, Saint-Hilaire JM et al. Divalproex extended-release versus the original divalproex tablet: results of a randomized, crossover study of well-controlled epileptic patients with primary generalized seizures. Epilepsy Res. 2002; 50:243-9.
13. Dutta S, Zhang Y, Selness DS et al. Comparison of the bioavailability of unequal doses of divalproex sodium extended-release formulation relative to the delayed-release formulation in healthy volunteers. Epilepsy Res. 2002; 49:1-10.
14. Sommerville KW, Dutta S, Biton V et al. Bioavailability of a divalproex extended-release formulation versus the conventional divalproex formulation in adult patients receiving enzyme-inducing antiepileptic drugs. Clin Drug Invest. 2003; 23:661-70.
15. Freitag FG, Collins SD, Carlson HA et al. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology. 2002; 58:1652-9.
16. Horne RL, Cunanan C. Safety and efficacy of switching psychiatric patients from a delayed-release to an extended-release formulation of divalproex sodium. J Clin Psychopharmacol. 2003; 23:176-81.
17. Cavanaugh JH, Granneman R, Lamm J et al. Effect of food on the bioavailability of a controlled-release formulation of Depakote under multiple-dose conditions. Epilepsia. 1997; 38(suppl 8):54.
18. Loiseau P, Cenraud B, Levy RH et al. Diurnal variations in steady-state plasma concentrations of valproic acid in epileptic patients. Clin Pharmacokinet. 1982; 7:544-52.
19. Riva R, Albani F, Cortelli P et al. Diurnal fluctuations in free and total plasma concentrations of valproic acid at steady state in epileptic patients. Ther Drug Monit. 1983; 5:191-6.
20. Bauer LA, Davis RD, Wilensky A et al. Diurnal variation in valproic acid clearance. Clin Pharmacol Ther. 1984; 35:505-9.
21. Ohdo S, Nakano S, Ogawa N. Circadian changes of valproate kinetics depending on meal condition in humans. J Clin Pharmacol. 1992; 32:822-6.
22. Hussein Z, Mukherjee D, Lamm J et al. Pharmacokinetics of valproate after multiple-dose oral and intravenous infusion administration: gastrointestinal-related diurnal variation. J Clin Pharmacol. 1994; 34:754-9.
23. Cloyd J. Pharmacokinetic pitfalls of present antiepileptic medications. Epilepsia. 1991; 32(suppl 5):S53-65.
24. Dutta S, Reed RC. Divalproex to divalproex-ER dose conversion: analysis of five distinct studies and dosing recommendations, www.aapspharmsci.org/ abstracts/AM_2003/AAPS2003-000631.pdf (accessed 2004 Jul14).
25. Dutta S, Reed RC, Cavanaugh JH. Absolute bioavailability and absorption characteristics of divalproex sodium extended-release tablets in healthy volunteers. J Clin Pharmacol. 2004; 44:737-42.